A meta-analysis of 85 randomized trials, published Oct. 24, 2026, in JAMA, found that SGLT2 inhibitors raised hemoglobin by 0.60 g/dL more than control, a small increase whose clinical meaning is still unclear.
A Medicare study published Oct. 1, 2026, in JAMA Network Open found that after the 2019 diabetes guideline update, SGLT2 inhibitor fills rose 11.4 percentage points in the patients it targeted, more among endocrinologists with higher knowledge scores.
In adults with type 2 diabetes starting a second medicine after metformin, SGLT-2 inhibitors or GLP-1 drugs lowered the five-year risk of kidney decline vs. DPP-4 inhibitors in people with protein in the urine (3.2% vs. 5.4%), but not in…